Go to the list of all blogs
Bort Wilson's Avatar
published in Blogs
Sep 26, 2026
SCHM vs SPMD: Weighing Two Low-Cost Mid-Cap ETFs

SCHM vs SPMD: Weighing Two Low-Cost Mid-Cap ETFs

Key Takeaways

  • Both SCHM and SPMD are low-cost passive ETFs providing exposure to U.S. mid-cap equities, with identical expense ratios of 0.03%.
  • SCHM tracks the Dow Jones U.S. Mid-Cap Total Stock Market Index with approximately 499 holdings, offering slightly broader diversification than SPMD, which follows the S&P MidCap 400 Index with around 402 holdings.
  • Sector allocations for both funds are concentrated in industrials, information technology, and financials, reflecting standard mid-cap blend characteristics with comparable risk profiles.
  • Top holdings in each ETF represent a modest percentage of assets, emphasizing diversified exposure rather than concentration in a few names.
  • Both funds employ physical replication and quarterly rebalancing aligned with their respective indices, resulting in low turnover and efficient tracking.
  • In the current mid-cap environment, structural similarities suggest investors may differentiate based on index methodology preferences rather than cost or liquidity.

Why These Two Mid-Cap ETFs Stand Out

Schwab U.S. Mid-Cap ETF (SCHM) and SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) compete directly as core holdings for investors seeking U.S. mid-cap equity exposure. Both ETFs target the middle segment of the market capitalization spectrum, where companies often exhibit growth potential combined with established operations. In the prevailing market environment characterized by sector rotation and interest rate dynamics, these funds offer investors alternative index methodologies for accessing similar segments of the equity market. I also checked this using Tickeron’s AI Screener to see how the holdings line up across peers.

Schwab U.S. Mid-Cap ETF (SCHM) at a Glance

The Schwab U.S. Mid-Cap ETF (SCHM) is a passively managed fund that seeks to track the Dow Jones U.S. Mid-Cap Total Stock Market Index. This index comprises approximately 499 mid-cap stocks ranked by market capitalization within the broader U.S. total stock market universe. The ETF maintains a diversified portfolio with top holdings typically accounting for less than 15% of assets combined, spanning sectors such as industrials and information technology. Its expense ratio stands at 0.03%, and it employs physical replication with periodic rebalancing to match index changes. Distinguishing features include broad mid-cap coverage that excludes most large- and small-cap constituents. From what I see, the wider holdings set gives it a slight edge in diversification.

SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) at a Glance

The SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) is a passively managed fund designed to track the S&P MidCap 400 Index. This benchmark includes approximately 402 mid-cap companies selected for their market capitalization, liquidity, and financial viability. The ETF features a concentrated yet diversified set of holdings, with top positions representing a modest share of the portfolio across industrials, financials, and technology sectors. It carries an expense ratio of 0.03% and uses physical replication with rebalancing aligned to index reconstitutions. Key characteristics include a focus on established mid-cap firms meeting specific inclusion criteria. One thing that stands out is how strictly the index applies its selection standards.

The Broader Mid-Cap Landscape

The U.S. mid-cap segment operates within a broader equity market influenced by macroeconomic factors including interest rate expectations, corporate earnings cycles, and sector rotation between growth and value styles. Regulatory developments in areas such as technology and healthcare, along with capital flows into domestic equities, continue to shape the environment. Both ETFs benefit from the mid-cap universe's balance of scale and agility, though they remain exposed to risks such as economic slowdowns affecting smaller-to-mid-sized companies and shifts in investor sentiment toward large-cap dominance. I’m watching this closely as rate decisions unfold.

How the Two Funds Compare in Practice

In recent market cycles, both SCHM and SPMD have demonstrated comparable volatility consistent with mid-cap benchmarks. Relative positioning has varied modestly with index composition differences, as SCHM captures a wider array of mid-cap names while SPMD adheres to stricter selection standards. Performance dynamics tie to broader themes such as industrial sector strength and technology adoption, with neither fund exhibiting significant structural advantages in liquidity or tracking efficiency over extended periods.

Exploring Tickeron’s AI Tools for ETF Research

In my own analysis, I often turn to Tickeron’s AI Screener when comparing funds like these. It lets me quickly filter mid-cap ETFs by holdings count, expense ratios, sector weights, and AI-driven signals, helping confirm that both SCHM and SPMD remain competitive on cost and diversification. The tool’s customizable scans make it straightforward to spot subtle differences in index methodology without manual number crunching. I’ve found it especially useful for staying on top of how these ETFs align with broader market themes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCHM, SPMD

Contributor

Bort Wilson's AvatarBort Wilson|Beginner

With a background in economics and swing trading, I write about market trends, technical setups, momentum, and opportunities that develop over several days or weeks. I combine economic perspective with practical trading experience to explain why stocks move, what trends may be developing, and which market signals are worth watching.


SCHM in -1.80% downward trend, sliding for three consecutive days on September 24, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SCHM declined for three days, in 215 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCHM as a result. In 67 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for SCHM turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 34 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

SCHM moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SCHM crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for SCHM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 52 cases where SCHM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +0.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHM advanced for three days, in 275 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

SCHM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are Bloom Energy Corp (NYSE:BE), Lumentum Holdings (NASDAQ:LITE), Moderna (NASDAQ:MRNA), Ciena Corp (NYSE:CIEN), Twilio (NYSE:TWLO), Okta (NASDAQ:OKTA), Centene Corp (NYSE:CNC), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Roku (NASDAQ:ROKU).

Industry description

The investment seeks to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Mid-Cap Total Stock Market Index. The index includes the mid-cap portion of the Dow Jones U.S. Total Stock Market Index actually available to investors in the marketplace. The Dow Jones U.S. Mid-Cap Total Stock Market Index includes the components ranked 501-1000 by full market capitalization. The index is a float-adjusted market capitalization weighted index. The fund will invest at least 90% of its net assets in securities included in the index.

Market Cap

The average market capitalization across the Schwab U.S. Mid-Cap ETF (SCHM) ETF is 13.2B. The market cap for tickers in the group ranges from 919.76M to 260.3B. SNDK holds the highest valuation in this group at 260.3B. The lowest valued company is BRBR at 919.76M.

High and low price notable news

The average weekly price growth across all stocks in the Schwab U.S. Mid-Cap ETF (SCHM) ETF was -1%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 14%. MRNA experienced the highest price growth at 29%, while MGM experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Schwab U.S. Mid-Cap ETF (SCHM) ETF was -48%. For the same stocks of the ETF, the average monthly volume growth was 1% and the average quarterly volume growth was -19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 53
Price Growth Rating: 54
SMR Rating: 59
Profit Risk Rating: 71
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
SCHM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category MidCapBlend

Category
Mid-Cap Blend
Address
Schwab Strategic Trust101 Montgomery StreetSan Francisco
Phone
1-800-435-4000
Web
www.csimfunds.com.
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.